Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant ...

Research continues on lung cancer, as rates of cancer rise among younger patients and women, UVA Cancer Center researchers ...

Received a "Study May Proceed” letter from the U.S. Food and Drug Administration (FDA ... the first-line treatment of ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Research and development expenses increased to $17.0 million for the three months ended September 30, 2024 from $15.4 million for the three months ended September 30, 2023 primarily due to ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

Researchers have combined two gene editing methods. This enables them to quickly investigate the significance of many genetic mutations involved in the development and treatment of cancer.

Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...